Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €71.50 EUR
Change Today -0.49 / -0.68%
Volume 0.0
RV6 On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 1:36 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (RV6) Snapshot

Open
€71.56
Previous Close
€71.99
Day High
€72.27
Day Low
€70.61
52 Week High
03/20/15 - €79.12
52 Week Low
05/5/14 - €36.02
Market Cap
3.4B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
47.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (RV6)

charles river laboratories (RV6) Related Bloomberg News

View More Bloomberg News

charles river laboratories (RV6) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (RV6) Details

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist its clients in supporting the use of research models in drug discovery and development comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target within a cell through delivery of clinical drug candidates; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides non-animal or in vitro methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and specific pathogen free fertile chicken eggs and chickens for the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,900 Employees
Last Reported Date: 02/17/15
Founded in 1947

charles river laboratories (RV6) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $530.3K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $524.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $518.1K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $587.5K
Compensation as of Fiscal Year 2014.

charles river laboratories (RV6) Key Developments

Charles River Laboratories International, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 11:35 AM

Charles River Laboratories International, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 11:35 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States.

Thomas F. Ackerman to Retire as Corporate Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. in February 2016

Charles River Laboratories International, Inc. announced planned management changes which will be implemented over the course of 2015. Thomas F. Ackerman, Corporate Executive Vice President and Chief Financial Officer, has announced that following a transition period, he will retire from Charles River Laboratories in February 2016. Mr. Ackerman has also agreed to provide periodic consulting services during the one-year period following his retirement, allowing the company to draw on his knowledge and experience.

Charles River Laboratories International, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 27, 2014; Provides Earnings Guidance for the Full Year of 2015

Charles River Laboratories International, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 27, 2014. For the quarter, the company reported net income attributable to common shareowners was $27,166,000 or $0.57 diluted earnings per share on total revenue of $329,548,000 against net income attributable to common shareowners of $19,099,000 or $0.40 diluted earnings per share on total revenue of $289,228,000 a year ago. The improvement in earnings per share was due primarily to higher revenue and operating income. Operating income was $40,767,000 and income from continuing operations before income taxes was $40,186,000 against operating income of $24,607,000 and income from continuing operations before income taxes of $23,106,000 a year ago. Income from continuing operations, net of tax was $28,536,000 or $0.59 per share against $19,526,000 or $0.40 per share a year ago. Non-GAAP revenue was $329,548,000 against $289,228,000 a year ago. Net income from continuing operations attributable to common shareholders, excluding specified charges (Non-GAAP) was $38,508,000 or $0.81 per diluted share against $35,116,000 or $0.73 per diluted share a year ago. For the year, the company reported net income attributable to common shareowners was $126,698,000 or $2.66 diluted earnings per share on total revenue of $1,297,662,000 against net income attributable to common shareowners of $102,828,000 or $2.12 diluted earnings per share on total revenue of $1,165,528,000 a year ago. Operating income was $177,670,000 and income from continuing operations before income taxes was $177,595,000 against operating income of 151,401,000 and income from continuing operations before income taxes of $138,327,000 a year ago. Income from continuing operations, net of tax was $129,924,000 or $2.70 per share against $105,416,000 or $2.15 per share a year ago. Non-GAAP revenue was $1,297,662,000 against $1,167,023,000 a year ago. Net income from continuing operations attributable to common shareholders, excluding specified charges (Non-GAAP) was $164,458,000 or $3.46 per diluted share against $142,252,000 or $2.93 per diluted share a year ago. Net cash provided by operating activities was $252,132,000 against $209,045,000 a year ago. Capital expenditures were $56,925,000 against $39,154,000 a year ago. For 2015, the company’s revenue growth is expected to be 6.0% to 7.5% on a constant-currency basis. Based on current rates, foreign currency translation is expected to reduce revenue growth by approximately 5%, which would result in reported revenue growth of 1.0% to 2.5%. Revenue growth in 2015 will be driven by the DSA and Manufacturing segments. Earnings per share are expected to benefit from higher sales and the company's ongoing global productivity and efficiency initiatives. These benefits are expected to be partially offset by foreign exchange, which is expected to reduce 2015 earnings per share by approximately $0.12. The company's s 2014 earnings per share include a $0.12 gain on limited-partnership investments; 2015 guidance includes an estimated $0.03 benefit from these investments. GAAP EPS is expected to be in the range of $3.15 to $3.25. Amortization of intangible assets is expected to be $0.31 million, operating losses to be $0.04 million and non-GAAP EPS estimate to be $3.55 to $3.65. The 2015 non-GAAP tax rate is expected to be in a range of 27% to 28%, which is similar to the 2014 rate of 27.4%. The company expects free cash flow to be in a range of $195 million to $205 million as continued improvement in operating cash flow is partially offset by higher CapEx. CapEx of up to $70 million in 2015 with the increase primarily a result of additional projects to drive revenue growth.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RV6:GR €71.50 EUR -0.49

RV6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.11 USD +0.06
Ergomed PLC 166.50 GBp 0.00
PAREXEL International Corp $67.49 USD +0.27
Quintiles Transnational Holdings Inc $69.09 USD +1.40
WuXi PharmaTech Cayman Inc $39.62 USD +0.26
View Industry Companies
 

Industry Analysis

RV6

Industry Average

Valuation RV6 Industry Range
Price/Earnings 28.8x
Price/Sales 2.8x
Price/Book 5.5x
Price/Cash Flow 24.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.